RHYTHM PHARMACEUTICALS, INC.

RYTM ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2017 FY2016 FY2015
Operating Activities
Net Income $-33.7M $-25.9M $-11.1M
Depreciation & Amortization $223.0K $144.0K
Depreciation
Amortization
Stock-Based Compensation $2.3M $1.2M $298.0K
Net Cash from Operating Activities $-29.5M $-23.2M $-7.0M
Investing Activities
Capital Expenditures $133.0K $1.1M $17.0K
Business Acquisitions
Net Cash from Investing Activities $-110.0M $-5.1M $-17.0K
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $167.2M $41.7M
Net Change in Cash $27.7M $-28.3M $34.7M
Free Cash Flow $-29.6M $-24.3M $-7.0M
← Newer Page 2 of 2 Older →